Long-term ouabain treatment impairs vascular function in resistance arteries

Journal of Vascular Research

Volumn 48, Issue 4, 2011, Pages 316-326

  Wenceslau, Camilla Ferreira ^a   Davel, Ana Paula ^a   Xavier, Fabiano Elias ^b   Rossoni, Luciana Venturini ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

COX 2; Ouabain induced hypertension; Oxidative stress; Pro inflammatory cytokines; Resistance arteries

Indexed keywords

CYTOKINE; DRUG VEHICLE; INTERLEUKIN 6; NORADRENALIN; OUABAIN; PROSTANOID; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTERY ENDOTHELIUM; ARTERY RESISTANCE; ARTICLE; BIOAVAILABILITY; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR EFFECT; CARDIOVASCULAR FUNCTION; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; CONTROLLED STUDY; HUMAN; MALE; MESENTERIC ARTERY; MYOGRAPHY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SYSTOLIC BLOOD PRESSURE;

ANIMALS; CYCLOOXYGENASE 2; ENDOTHELIUM, VASCULAR; HYPERTENSION; MALE; MESENTERIC ARTERIES; NITRIC OXIDE; OUABAIN; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; SUPEROXIDES; SYSTOLE; VASCULAR RESISTANCE; VASOCONSTRICTION;

EID: 79151475651     PISSN: 10181172     EISSN: 14230135     Source Type: Journal    
DOI: 10.1159/000322576     Document Type: Article

References (43)

1. Laredo J, Hamilton BP, Hamlyn JM: Ouabain is secreted by bovine adrenocortical cells. Endocrinology 1994;135:794-797. (Pubitemid 24241265)
2. Schoner W, Scheiner-Bobis G: Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. Am J Physiol 2007;293:C509-C536. (Pubitemid 47235171)
3. Bagrov AY, Shapiro JI: Endogenous digitalis: pathophysiologic roles and therapeutic applications. Nat Clin Pract Nephrol 2008;4:378-392. (Pubitemid 351913708)
4. Blaustein MP, Zhang J, Chen L, Song H, Raina H, Kinsey SP, Izuka M, Iwamoto T, Kotlikoff MI, Lingrel JB, Philipson KD, Wier WG and Hamlyn JM: The pump, the exchanger, and endogenous ouabain. Hypertension 2009;53:291-298.
5. Overbeck HW, Pamnani MB, Akera T, Brody TM, Haddy FJ: Depressed function of a ouabain- sensitive sodium-potassium pump in blood vessels from renal hypertensive dogs. Circ Res 1976;38:48-52.
6. +) ATPase associated with essential hypertension. Nature 1982;300:650-652.
7. Yuan CM, Manuta P, Hamlyn JM, Chen S, Bohen E, Yeun J, Haddy FJ, Pammani MB: Long-term ouabain administration produces hypertension in rats. Hypertension 1993;22:178-187. (Pubitemid 23234064)
8. Kimura K, Manunta P, Hamilton BP, Hamlyn JM: Different effects of in vivo ouabain and digoxin on renal artery function and blood pressure in the rat. Hypertension Res 2000;23:67-76.
9. +-ATPase in ouabain-induced hypertension. Br J Pharmacol 2002;135:771-781.
10. Rossoni LV, Salaices M, Miguel M, Briones, AM, Barker LA, Vassallo DV, Alonso MJ: Ouabain-induced hypertension is accompanied by increases in endothelial vasodilator factors. Am J Physiol Heart Circ Physiol 2002;283:H2110-H2118. (Pubitemid 35217045)
11. Xavier FE, Salaices M, Marquez-Rodas I, Alonso MJ, Rossoni LV, Vassallo DV, Balfagón G: Neurogenic nitric oxide release increases in mesenteric arteries from ouabain hypertensive rats. J Hypertens 2004;22:949-957. (Pubitemid 38680470)
12. Xavier FE, Rossoni LV, Alonso MJ, Balfagón G, Vassallo DV, Salaices M: Ouabain-induced hypertension alters the participation of endothelial factors in α-adrenergic responses differently in rat resistance and conductance mesenteric arteries. Br J Pharmacol 2004;143:215-225. (Pubitemid 39280041)
13. Xavier FE, Yogi A, Callera GE, Tostes RC, Alvarez Y, Salaices M, Alonso MJ, Rossoni LV: Contribution of the endothelin and reninangiotensin systems to the vascular changes in rats chronically treated with ouabain. Br J Pharmacol 2004;143:794-802. (Pubitemid 39611615)
14. Briones AM, Xavier FE, Arribas SM, González MC, Rossoni LV, Alonso MJ, Salaices M: Alterations in structure and mechanics of resistance arteries from ouabain induced hypertensive rats. Am J Physiol Heart Circ Physiol 2006;291:H193-H201.
15. Huang BS, Huang X, Harmsen E, Leenen FHH: Chronic central versus peripheral ouabain, blood pressure, and sympathetic activity in rats. Hypertension 1994;23:1087-1090. (Pubitemid 24180872)
16. Huang BS, Leenen FHH: Brain renin-angiotensin system and ouabain induced sympathetic hyperactivity and hypertension in Wistar rats. Hypertension 1999;34:107-112. (Pubitemid 29325727)
17. Di Filippo C, Filippelli A, Rinaldi B, Piegari E, Esposito F, Rossi F, D'Amico M: Chronic peripheral ouabain treatment affects the brain endothelin system of rats. J Hypertens 2003;21:747-753. (Pubitemid 36549670)
18. Hernanz R, Briones AM, Nartin A, Beltrán AE, Tejerina T, Salaices M, Alonso MJ: Ouabain treatment increases nitric oxide bioavailability and decreases superoxide anion production in cerebral vessels. J Hypertens 2008;26:1944-1954.
19. Padilha AS, Peçanha FM, Vassallo DV, Alonso MJ, Mercedes S: Ouabain treatment changes the role of endothelial factors in rat resistance arteries. Eur J Pharmacol 2008; 600:100-116.
20. Cao C, Payne K, Lee-Kwon W, Zhang Z, Lim SW, Hamlyn J, Blaustein MP, Kwon HM, Pallone TL: Chronic ouabain treatment induces vasa recta endothelial dysfunction in the rat. Am J Physiol Renal Physiol 2009;296:F98-F106.
21. Xavier FE, Davel AP, Fukuda LE, Rossoni LV: Chronic ouabain treatment exacerbates blood pressure elevation in spontaneously hypertensive rats: the role of vascular mechanisms. J Hypertens 2009;27:1233-1242.
22. Mulvany MJ, Halpern W: Mechanical properties of vascular smooth cells in situ. Nature 1977:260:617-619.
23. Davel AP, Kawamoto EM, Scavone C, Vassallo DV, Rossoni LV: Changes in vascular reactivity following administration of isoproterenol for 1 week:a role for endothelial modulation. Br J Pharmacol 2006;148:629-639. (Pubitemid 43993053)
24. Manunta P, Hamilton J, Rogowski AC, Hamilton BP, Hamlyn JM: Chronic hypertension induced by ouabain but not digoxin in the rat:antihypertensive effect of digoxin and digitoxin. Hypertens Res 2000;23(suppl):S77-S85.
25. Zhang J, Hamlyn JM, Karashima E, Raina H, Mauban JRH, Izuka M, Berra-Romani R, Zulian A, Wier G, Blaustein M: Low-dose ouabain constricts small arteries from ouabain- hypertensive rats: implications for sustained elevation of vascular resistance. Am J Physiol Heart Circ Physiol 2009;297:H1140-H1150.
26. Christensen KL, Mulvany MJ: Location of resistance arteries. J Vasc Res 2001;38:1-12. (Pubitemid 32171094)
27. Rubanyi GM, Vanhoutte PM: Oxygen-derived free radicals, endothelium, and responsiveness of vascular smooth muscle. Am J Physiol 1986;250:H815-H821.
28. Touyz RM: Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension 2004;44:248-252.
29. Aizman O, Uhlén P, Lal M, Brismar H, Aperia A:Ouabain, a steroid hormone that signals with slow calcium oscillations. Proc Natl Acad Sci USA 2001;98:13420-13424. (Pubitemid 33051378)
30. Valente RC, Capella LS, Monteiro RQ, Rumjanek VM, Lopes AG, Capella MAM: Mechanisms of ouabain toxicity. FASEB J 2003;17:1700-1702.
31. Alvarez Y, Briones AM, Balfagón G, Alonso MJ, Salaices M: Hypertension increases the participation of vasoconstrictor prostanoids from cyclooxygenase-2 in phenylephrine responses. J Hypertens 2005;23:767-777. (Pubitemid 40523275)
32. Vanhoutte PM, Feletou M, Taddei S: Endothelium- dependent contractions in hypertension. Br J Pharmacol 2005;144:449-458.
33. Lüscher TF, Vanhoutte PM: Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension 1986;8:344-348. (Pubitemid 16042204)
34. +-ATPase activity in the tail artery from L -NAME-treated rats. Life Sci 2003;74:613-627.
35. Xavier FE, Aras-López R, Arroyo-Villa I, Campo LD, Salaices M, Rossoni LV, Ferrer M, Balfagón G: Aldosterone induces endothelial dysfunction in resistance arteries from normotensive and hypertensive rats by increasing thromboxane A2 and prostacyclin. Br J Pharmacol 2008;154:1225-1235. (Pubitemid 351992068)
36. +-ATPase on the prostacyclin generation of cultured human vascular endothelial cells. Life Sci 1987;40:351-357.
37. Hernanz R, Briones AM, Alonso MJ, Vila E, Salaices M: Hypertension alters role of iNOS, COX-2, and oxidative stress in bradykinin relaxation impairment after LPS in rat cerebral arteries. Am J Physiol Heart Circ Physiol 2004;258:H225-H234. (Pubitemid 38802357)
38. Vila E, Salaices M: Cytokines and vascular reactivity in resistance arteries. Am J Physiol Heart Circ Physiol 2005;288:H1016-H1021. (Pubitemid 40270001)
39. Virdis A, Schiffrin EL: Vascular inflammation: a role in vascular disease in hypertension? Opin Nephrol Hypertens 2003;12:181-187.
40. Nedeljkovic ZS, Gokce N, Loscalzo J: Mechanisms of oxidative stress and vascular dysfunction. Postgrad Med J 2003;79:195-200. (Pubitemid 36605780)
41. Matsumori A, Ono K, Nishio R, Igata H, Shioi T, Matsui S, Furukawa Y, Iwasaki A, Nose Y: Modulation of cytokine production and protection against lethal endotoxemia by the cardiac glycoside ouabain. Circulation 1997;96:1501-1506. (Pubitemid 27375343)
42. Bereta J, Cohen MC, Bereta M: Stimulatory effect of ouabain on VCAM-1 and iNOS expression in murine endothelial cells: involvement of NF-κB. FEBS Lett 1995;377:21-25. (Pubitemid 26009775)
43. Ferrari P, Torielli L, Ferrandi M, Padoani G, Duzzi L, Florio M, Conti F, Melloni P, Vesci L, Corsico N, Bianchi G: PST2238: a new antihypertensive compound that antagonizes the long-term pressor effect of ouabain. J Pharmacol Exp Ther 1998;285:83-94. (Pubitemid 28207572)